Brand Name
Bizengri
Generic Name
Zenocutuzumab
View Brand Information FDA approval date: December 04, 2024
Form: Injection
What is Bizengri (Zenocutuzumab)?
BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment